NCT00000884View on ClinicalTrials.gov

A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

October 31, 2000

Conditions

HIV Infections

Interventions

BIOLOGICAL

MN rgp120/HIV-1 and GNE8 rgp120/HIV-1

Dosage will vary based on route of administration

BIOLOGICAL

ALVAC-HIV MN120TMG (vCP205)

Dosage will vary based on route of administration

BIOLOGICAL

ALVAC-RG Rabies Glycoprotein (vCP65)

Dosage will vary based on route of administration

Trial Locations (6)

14642

Univ. of Rochester AVEG, Rochester

35294

UAB AVEG, Birmingham

37232

Vanderbilt Univ. Hosp. AVEG, Nashville

63104

St. Louis Univ. School of Medicine AVEG, St Louis

98144

UW - Seattle AVEG, Seattle

Unknown

JHU AVEG, Baltimore

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000884 - A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult Volunteers | Biotech Hunter | Biotech Hunter